SCHEDULE: Vanguard Group Reports 0% Stake in Ocular Therapeutix

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Ocular Therapeutix Inc. due to an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to Schedule 13G for Ocular Therapeutix Inc. Common Stock.
• The filing reports that The Vanguard Group now beneficially owns 0.00 shares, representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group, Inc., which became effective on January 12, 2026.
• Following this realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Ocular Therapeutix Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Ocular Therapeutix Inc. because the 0% beneficial ownership reported by The Vanguard Group is due to an internal corporate realignment and disaggregated reporting by its subsidiaries, rather than a complete divestment by all Vanguard-affiliated entities.

Positives

• The change in reported ownership is due to an internal corporate realignment by Vanguard, not necessarily a complete divestment by all Vanguard-affiliated entities.
• The filing explicitly states the securities were held in the ordinary course of business and not for influencing control, indicating no activist intent.

Negatives

• The Vanguard Group, as the parent entity, no longer reports any direct beneficial ownership in Ocular Therapeutix Inc.

Risks

• There is a potential for market misinterpretation if investors perceive the 0% stake reported by The Vanguard Group as a complete divestment by all Vanguard-affiliated funds, rather than a technical reporting change.

Future Outlook

No forward-looking statements or guidance regarding Ocular Therapeutix Inc.'s operations or financial performance are provided in this filing.

Industry Context

StockSavvy.ai notes that a major institutional investor like The Vanguard Group reporting a 0% stake in a company is typically a significant event. However, in this specific instance, the change is attributed to an internal corporate realignment where subsidiaries will now report separately. This suggests that the underlying investment by Vanguard-affiliated funds may still exist, but the reporting structure has changed, making it a technical rather than a fundamental shift in investment thesis by the broader Vanguard organization.

Comparison to Industry Standards

• StockSavvy.ai observes that large asset managers frequently undergo internal restructurings or changes in reporting methodologies. For example, similar disaggregated reporting changes have been seen with other large fund families where specific funds or advisory arms report independently.
• This is a common practice for large, complex financial institutions to comply with regulatory guidance like SEC Release No. 34-39538, rather than an indication of a specific investment decision against Ocular Therapeutix Inc.

Stakeholder Impact

• Shareholders: May initially perceive the 0% stake as a negative signal, but understanding the internal realignment context should mitigate concerns. The actual impact on the company's stock price will depend on how the market interprets this technical reporting change.

Key Dates

Recommendation

The filing indicates a technical change in reporting by The Vanguard Group due to an internal realignment, rather than a fundamental shift in investment thesis regarding Ocular Therapeutix Inc. While the parent entity now reports 0% ownership, Vanguard-affiliated subsidiaries may still hold shares and will report them separately. Therefore, a 'hold' recommendation is appropriate as this event does not inherently alter the investment fundamentals of Ocular Therapeutix Inc., but investors should monitor future filings from Vanguard's subsidiaries for clarity on overall Vanguard family holdings.

Keywords

Ocular Therapeutix, Vanguard Group, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional ownership, corporate realignment